-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
Bi/Multi Specifics
Successful bispecific antibody production requires the correct assembly of multiple peptide chains t
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Drinks-Canape Reception
-
Bi/Multispecifics
Do complex sequences show an impact on titer, proper assembly, and purification? Do you face issues
...
-
Formats & Scaffolds
Single domain antibodies are incredibly versatile and increasingly appear in clinical pipelines. Wha
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
What are the key issues faced in the in vitro degradation of antibodies, and which (bio)chemical pat
...
-
Formats & Scaffolds
Given the unique biology of antibody maturation in rabbits, this species is an excellent source for
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
The computational development of antibodies is an emerging industry that has become feasible thanks
...
-
Antibody Drug Conjugates
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Afternoon Refreshments
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
In today’s biologics drug development landscape, flexible, end-to-end solutions are crucial for adva
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Networking Lunch
-
Bi/Multispecifics
What are the main driving forces to bring more BsAbs to the market compared to mAbs? What would be
...
-
Formats & Scaffolds
In silico and in vitro immunogenicity assessment as a de-risking strategy Approaches to mitigate the
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
How can we increase hit diversity from screening outputs using NGS with AI/ML? How can improve antib
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Morning Refreshments
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
Bi/Multispecifics
Optimal design for a multispecific TCE - what have we learned and what do we still need to learn? Ho
...
-
Formats & Scaffolds
Optimal rationale design for CIS versus TRANS-potency (target selection, novel masking strategies) A
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
A preponderance of positively-charged residues (R, K) in the paratope of antibodies can lead to poly
...
-
Antibody Drug Conjugates
Antigen Heterogeneity: Tumor cells often express various antigens, making it difficult to identify u
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Current ADCs still display poor translation of their preclinical therapeutic window into the clinic,
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Registration